Mikkel Bring Christensen

List of Publications by Year
in descending order

114 papers	4,609 citations	126907 33 h-index	110387 64 g-index
120 all docs	120 docs citations	120 times ranked	4760 citing authors

#	Article	IF	Citations
1	Glucoseâ€dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, doubleâ€blind, placeboâ€controlled, crossover clinical trial. Diabetes, Obesity and Metabolism, 2022, 24, 142-147.	4.4	4
2	Glucagon Clearance Is Preserved in Type 2 Diabetes. Diabetes, 2022, 71, 73-82.	0.6	6
3	Acute changes in plasma glucose increases left ventricular systolic function in insulinâ€treated patients with type 2 diabetes and controls. Diabetes, Obesity and Metabolism, 2022, 24, 1123-1131.	4.4	3
4	LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men. Cell Reports Medicine, 2022, 3, 100582.	6.5	21
5	Effects of a comprehensive medication review intervention on healthâ€related quality of life and other clinical outcomes in geriatric outpatients with polypharmacy: A pragmatic randomized clinical trial. British Journal of Clinical Pharmacology, 2022, 88, 3360-3369.	2.4	10
6	Acute concomitant glucoseâ€dependent insulinotropic polypeptide receptor antagonism during glucagonâ€like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity. Diabetes, Obesity and Metabolism, 2022, 24, 1882-1887.	4.4	5
7	Shortâ€term mortality following tramadol poisonings in Denmark. Basic and Clinical Pharmacology and Toxicology, 2022, 131, 83-92.	2.5	5
8	Drug use in patients with short bowel syndrome and intestinal failure.. Danish Medical Journal, 2022, 69, .	0.5	0
9	A poison information centre can provide important assessment and guidance regarding medication errors in nursing homes: A prospective cohort study. Basic and Clinical Pharmacology and Toxicology, 2021, 128, 542-549.	2.5	0
10	Identification and Metabolic Profiling of a Novel Human Gut-derived LEAP2 Fragment. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e966-e981.	3.6	22
11	Doseâ€dependent efficacy of the glucoseâ€dependent insulinotropic polypeptide (<scp>GIP)</scp> receptor antagonist <scp>GIP</scp>(3â€30)<scp>NH₂</scp> on <scp>GIP</scp> actions in humans. Diabetes, Obesity and Metabolism, 2021, 23, 68-74.	4.4	14
12	An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight. Diabetes, Obesity and Metabolism, 2021, 23, 17-35.	4.4	27
13	Pancreatic polypeptide: A potential biomarker of glucoseâ€dependent insulinotropic polypeptide receptor activation in vivo. Diabetic Medicine, 2021, 38, e14592.	2.3	1
14	Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls. European Journal of Endocrinology, 2021, 185, 343-353.	3.7	12
15	Causes of discrepancies between medications listed in the national electronic prescribing system and patients' actual use of medications. Basic and Clinical Pharmacology and Toxicology, 2021, 129, 221-231.	2.5	10
16	Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998â€“2018. Scientific Reports, 2021, 11, 13603.	3.3	8
17	Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opinion on Emerging Drugs, 2021, 26, 231-243.	2.4	51
18	Effects of endogenous GIP in patients with type 2 diabetes. European Journal of Endocrinology, 2021, 185, 33-45.	3.7	21

#	Article	IF	Citations
19	The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial. Diabetologia, 2021, 64, 2425-2431.	6.3	4
20	Exendin(9â€39)<scp>NH₂</scp>: Recommendations for clinical use based on a systematic literature review. Diabetes, Obesity and Metabolism, 2021, 23, 2419-2436.	4.4	15
21	Mechanisms in Endocrinology: The physiology of neuronostatin. European Journal of Endocrinology, 2021, 185, R93-R101.	3.7	0
22	Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes. ELife, 2021, 10, .	6.0	20
23	Two-bag intravenous N-acetylcysteine, antihistamine pretreatment and high plasma paracetamol levels are associated with a lower incidence of anaphylactoid reactions to N-acetylcysteine. Clinical Toxicology, 2020, 58, 698-704.	1.9	9
24	GIP and the gut-bone axis â€“ Physiological, pathophysiological and potential therapeutic implications. Peptides, 2020, 125, 170197.	2.4	25
25	Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides, 2020, 125, 170183.	2.4	61
26	GIPâ€™s involvement in the pathophysiology of type 2 diabetes. Peptides, 2020, 125, 170178.	2.4	18
27	Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e502-e510.	3.6	12
28	GIPâ€™s effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3â€“30)NH2. Bone, 2020, 130, 115079.	2.9	20
29	Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease. Peptides, 2020, 125, 170174.	2.4	27
30	The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. Bone, 2020, 140, 115553.	2.9	25
31	Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes. Journal of the Endocrine Society, 2020, 4, bvaa097.	0.2	12
32	Medication-related experiences of patients with polypharmacy: a systematic review of qualitative studies. BMJ Open, 2020, 10, e036158.	1.9	25
33	Highâ€Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Betaâ€Adrenoceptor Blockade: A Randomized Clinical Trial. Journal of the American Heart Association, 2020, 9, e016828.	3.7	15
34	Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years. Scientific Reports, 2020, 10, 4095.	3.3	6
35	Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent. Neurochemistry International, 2020, 138, 104772.	3.8	11
36	What is on the horizon for type 2 diabetes pharmacotherapy? â€“ An overview of the antidiabetic drug development pipeline. Expert Opinion on Drug Discovery, 2020, 15, 1253-1265.	5.0	6

#	Article	IF	Citations
37	Total burden of disease in cancer patients at diagnosisâ€"a Danish nationwide study of multimorbidity and redeemed medication. British Journal of Cancer, 2020, 123, 1033-1040.	6.4	17
38	Clinical pharmacology of imeglimin for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy, 2020, 21, 871-882.	1.8	10
39	GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e725-e738.	3.6	37
40	No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes. Diabetes Care, 2020, 43, 588-596.	8.6	38
41	GIP(3-30)NH2 â€“ a tool for the study of GIP physiology. Current Opinion in Pharmacology, 2020, 55, 31-40.	3.5	8
42	89-LB: The Effect of GIP on Plasma Glucose in a Setting of Prandial Insulin Overdose and Physical Activity after Meal Intake in Patients with Type 1 Diabetes. Diabetes, 2020, 69, .	0.6	3
43	Effect of a medicines management model on medicationâ€related readmissions in older patients admitted to a medical acute admission unitâ€"A randomized controlled trial. Journal of Evaluation in Clinical Practice, 2019, 25, 88-96.	1.8	21
44	The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretionâ€"A Review. International Journal of Molecular Sciences, 2019, 20, 4092.	4.1	47
45	Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. Diabetologia, 2019, 62, 665-675.	6.3	81
46	Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2953-2960.	3.6	41
47	THU0670â€...PATERNAL USE OF METHOTREXATE AND CONGENITAL MALFORMATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS. , 2019, , .		0
48	Hemodynamic Effects of Intravenous, Highâ€Dose Lipid Emulsion With and Without Metoprolol Infusion in Healthy Volunteers: A Randomized Clinical Trial. Clinical Pharmacology and Therapeutics, 2019, 105, 1009-1017.	4.7	3
49	Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. Diabetes, 2019, 68, 906-917.	0.6	118
50	Long term treatment with stimulant laxatives â€“ clinical evidence for effectiveness and safety?. Scandinavian Journal of Gastroenterology, 2019, 54, 27-34.	1.5	28
51	64-OR: Postprandial Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide in Type 2 Diabetes. Diabetes, 2019, 68, .	0.6	10
52	Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 288-294.	3.6	64
53	Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents. Peptides, 2018, 100, 173-181.	2.4	56
54	A Systematic Review on Insulin Overdose Cases: Clinical Course, Complications and Treatment Options. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 650-659.	2.5	25

#	Article	IF	Citations
55	GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. Diabetologia, 2018, 61, 413-423.	6.3	66
56	Important Aspects of Pharmacistâ€led Medication Reviews in an Acute Medical Ward. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 253-261.	2.5	9
57	Overdoses with Aripiprazole: Signs, Symptoms and Outcome in 239 Exposures Reported to the Danish Poison Information Centre. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 293-298.	2.5	10
58	Outcomes following calcium channel blocker exposures reported to a poison information center. BMC Pharmacology & Toxicology, 2018, 19, 78.	2.4	8
59	General Practitionersâ€™ Barriers Toward Medication Reviews in Polymedicated Multimorbid Patients. Health Services Research and Managerial Epidemiology, 2018, 5, 233339281879216.	0.9	13
60	Response to Letter to the Editor: â€œHemodynamic Effects of Glucagon: A Literature Reviewâ€. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4480-4481.	3.6	0
61	Polypharmacy and medication deprescribing: A survey among multimorbid older adults in Denmark. Pharmacology Research and Perspectives, 2018, 6, e00431.	2.4	30
62	Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects. Metabolic Syndrome and Related Disorders, 2018, 16, 530-536.	1.3	22
63	Preclinical discovery and development of colesevelam for the treatment of type 2 diabetes. Expert Opinion on Drug Discovery, 2018, 13, 1161-1167.	5.0	9
64	Effects of high-dose, intravenous lipid emulsion on laboratory tests in humans: a randomized, placebo-controlled, double-blind, clinical crossover trial. Clinical Chemistry and Laboratory Medicine, 2018, 56, 2047-2057.	2.3	3
65	Hemodynamic Effects of Glucagon: A Literature Review. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1804-1812.	3.6	43
66	Postprandial Effects of Individual and Combined GIP and GLP-1 Receptor Antagonization in Healthy Subjects. Diabetes, 2018, 67, 145-OR.	0.6	3
67	Mono- and Co-Activation of the GIP and GLP-1 Receptors Inhibits Bone Resorption. Diabetes, 2018, 67, .	0.6	4
68	Topical pharmacological treatment of hemorrhoids during pregnancy and congenital malformations - a nation-wide cohort study. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-5-16.	0.0	0
69	Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide. Clinical Pharmacokinetics, 2017, 56, 719-731.	3.5	18
70	Quality of care for people with multimorbidity â€“ a case series. BMC Health Services Research, 2017, 17, 745.	2.2	22
71	Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0166125.	2.5	188
72	Searching for the physiological role of glucoseâ€dependent insulinotropic polypeptide. Journal of Diabetes Investigation, 2016, 7, 8-12.	2.4	30

#	Article	IF	Citations
73	Speciesâ€specific action of (Pro3)GIP â€“ a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. British Journal of Pharmacology, 2016, 173, 27-38.	5.4	86
74	Nâ€terminally and Câ€terminally truncated forms of glucoseâ€dependent insulinotropic polypeptide are highâ€affinity competitive antagonists of the human GIP receptor. British Journal of Pharmacology, 2016, 173, 826-838.	5.4	72
75	Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network metaâ€analysis. British Journal of Clinical Pharmacology, 2016, 82, 1291-1302.	2.4	39
76	Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4377-4384.	3.6	12
77	Medication review in hospitalised patients to reduce morbidity and mortality. The Cochrane Library, 2016, 2016, CD008986.	2.8	179
78	Effects of glucose-dependent insulinotropic polypeptide on glucagon. Cardiovascular Endocrinology, 2016, 5, 75-81.	0.8	1
79	Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2076-2083.	3.6	24
80	Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes, 2016, 65, 585-597.	0.6	136
81	An alternative combination therapy for type 2 diabetes?. Lancet, The, 2015, 385, 2020-2022.	13.7	1
82	Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1493-1503.	3.3	13
83	Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes. International Journal of Obesity, 2015, 39, 1651-1654.	3.4	41
84	Glucose-Dependent Insulinotropic Polypeptide Augments Glucagon Responses to Hypoglycemia in Type 1 Diabetes. Diabetes, 2015, 64, 72-78.	0.6	60
85	Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist. Clinical Investigation, 2014, 4, 729-743.	0.0	3
86	Glucose-Dependent Insulinotropic Polypeptide Inhibits Bone Resorption in Humans. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2325-E2329.	3.6	104
87	Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care. Clinical Toxicology, 2014, 52, 39-43.	1.9	21
88	Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. European Journal of Endocrinology, 2014, 170, 529-538.	3.7	116
89	Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E418-E426.	3.6	79
90	Glucagon and Type 2 Diabetes: the Return of the Alpha Cell. Current Diabetes Reports, 2014, 14, 555.	4.2	96

#	Article	IF	Citations
91	The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. Expert Opinion on Drug Discovery, 2014, 9, 1223-1251.	5.0	23
92	Elimination and Degradation of Glucagon-like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Patients with End-Stage Renal Disease. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2457-2466.	3.6	31
93	The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials. BMJ Open, 2014, 4, e005378-e005378.	1.9	4
94	Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia, 2013, 56, 965-972.	6.3	199
95	Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes. Diabetes Care, 2013, 36, 3346-3352.	8.6	125
96	GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 17-29.	3.3	49
97	Medication review in hospitalised patients to reduce morbidity and mortality. , 2013, , CD008986.		64
98	Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2013, 6, 217.	2.4	37
99	Comment on: Gogebakan et al. Glucose-Dependent Insulinotropic Polypeptide Reduces Fat-Specific Expression and Activity of 11Â-Hydroxysteroid Dehydrogenase Type 1 and Inhibits Release of Free Fatty Acids. Diabetes 2012;61:292-300. Diabetes, 2012, 61, e12-e12.	0.6	1
100	Add-on to metformin in T2DMâ€"linagliptin or glimepiride?. Nature Reviews Endocrinology, 2012, 8, 576-578.	9.6	0
101	The unobtainable placebo: control of independent clinical research by industry?. Lancet, The, 2012, 379, 30.	13.7	12
102	Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ: British Medical Journal, 2012, 344, d7771-d7771.	2.3	731
103	Authors' reply to de Oliveira and Iverson. BMJ: British Medical Journal, 2012, 344, e1459-e1459.	2.3	0
104	Regulation of glucagon secretion by incretins. Diabetes, Obesity and Metabolism, 2011, 13, 89-94.	4.4	132
105	Lixisenatide for type 2 diabetes mellitus. Expert Opinion on Investigational Drugs, 2011, 20, 549-557.	4.1	70
106	The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist. Expert Review of Endocrinology and Metabolism, 2011, 6, 513-525.	2.4	5
107	Glucose-Dependent Insulinotropic Polypeptide. Diabetes, 2011, 60, 3103-3109.	0.6	265
108	Therapy for Obesity Based on Gastrointestinal Hormones. Review of Diabetic Studies, 2011, 8, 339-347.	1.3	9

#	Article	IF	Citations
109	The Alpha-Cell as Target for Type 2 Diabetes Therapy. Review of Diabetic Studies, 2011, 8, 369-381.	1.3	49
110	Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?. Current Diabetes Reports, 2010, 10, 124-132.	4.2	42
111	Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes. Regulatory Peptides, 2010, 163, 96-101.	1.9	18
112	Prehospital evaluation of patients with chronic obstructive pulmonary disease. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2009, 17, P10.	2.6	0
113	Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs: the Investigational Drugs Journal, 2009, 12, 503-13.	0.7	26
114	Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in Beta Cell Function in Patients with Type 2 Diabetes. Diabetes, 0, , .	0.6	1